Oviva secures €200m to expand digital chronic care across Europe

Oviva, a Swiss digital healthcare provider specialising in reimbursed programmes for weight-related and chronic conditions, has completed a €200 million (US$234m) Series D funding round, one of the largest in digital health to date.

The investment will accelerate the company’s expansion across chronic indications such as hypertension and type 2 diabetes, enhancing access to continuous care and preventative interventions.

The round was led by Sweden-based Kinnevik, investing €100 million, with participation from Planet First Partners, A.P. Moller Holding, Lunate, EGS Beteiligungen AG, Norrsken VC, and ongoing support from existing investor Sofina. Following the investment, Kinnevik becomes Oviva’s largest shareholder, joining a growing group of long-term backers.

CEO Kai Eberhardt highlighted the strategic impact of the funding: “This investment allows us to do what we set out to do: make effective care accessible to everyone who needs it. By intervening earlier and supporting patients continuously over time, we help prevent disease progression, free up clinical capacity, and enable healthcare systems to deliver better outcomes with limited resources.”

Christian Scherrer, senior investment director at Kinnevik, added: “Oviva has demonstrated that digital care can deliver measurable health outcomes at scale. By addressing some of the most pressing and costly conditions, we believe the company is already transforming health economics for the heavily strained European healthcare systems.”

Founded in 2014 by Kai Eberhardt and Manuel Baumann, Oviva has served over one million people across Germany, the UK, and Switzerland. Its programmes are fully reimbursed in these core markets, working closely with public health systems, insurers, and clinicians.

Explore how Oviva’s expansion is redefining digital chronic care delivery across European healthcare systems.